Login
Titan Medical NASDAQ: TMDI
Titan Medical, Inc. engages in the design, development, and commercialization of new robotic surgical technologies for application in minimally invasive surgery.
| Name | Titan Medical |
| Ticker | TMDI |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Medical Robotics |
|
Price
52W Low/High |
1.63
0.24 / 3.23 |
| Momentum | Sharp Down |
| Market cap | 65 M |
| 1Y Total Return |
565.31%
Strong |
| 1Y Volatility |
206.09%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Titan Medical, Inc. engages in the design, development, and commercialization of new robotic surgical technologies for application in minimally invasive surgery.
Details
| Ticker | TMDI |
| Name | Titan Medical |
| ISIN | CA88830X8199 |
| CUSIP | 88830X819 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Medical Robotics |
| Country | Canada |
| Currency | U.S. Dollar |
Share as of 4/15/21
| Close Price | 1.63 |
| 52W Low/High | 0.24 / 3.23 |
| Market cap | 65 M |
| 1Y Total Return |
565.31%
Strong |
| 1Y Volatility |
206.09%
High Risk |
| Beta | 6.10 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -120.9% |
| Cash from Op. / Cur. Liabilities | -0.02 |
| Diluted Earnings / Share | -0.36 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 5.5 |
| Price / Book | -7.9 |
| Price / CF | -129.2 |
| Current Ratio | 0.6 |
| Cur.Liabilities / Tot.Liabilities | 1.0 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to December
|
|||||
|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
20
|
0
|
0
|
0
|
-
|
|
| Gross Profit |
20
|
-
|
-
|
-
|
-
|
|
| R&D |
8
|
51
|
33
|
13
|
-
|
|
| EBITDA |
-23
|
-41
|
-23
|
-34
|
-
|
|
| Operating Income |
4
|
-59
|
-40
|
-19
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
|
| per Share | ||||||
| Diluted avg Shares |
67
|
31
|
17
|
8
|
-
|
|
| EPS exc. Extra |
-0.36
|
-1.37
|
-1.36
|
-4.25
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
30
|
3
|
22
|
30
|
7
|
|
| Cash, Eq & Invt ShortTerm |
26
|
1
|
20
|
29
|
6
|
|
| Total Current Assets |
27
|
2
|
21
|
29
|
7
|
|
| Total Non-Current Assets |
3
|
2
|
1
|
1
|
1
|
|
| Intangibles |
2
|
2
|
1
|
1
|
1
|
|
| Total Liabilities |
44
|
15
|
18
|
20
|
7
|
|
| Total Current Liabilities |
43
|
15
|
18
|
20
|
7
|
|
| Long Term Debt |
1
|
0
|
0
|
0
|
0
|
|
| Shareholder equity |
-14
|
-12
|
4
|
10
|
1
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-1
|
-46
|
-41
|
-19
|
-
|
|
| Depreciation |
0
|
0
|
0
|
0
|
-
|
|
| Cash from Investing |
-1
|
0
|
0
|
0
|
-
|
|
| Capex |
0
|
0
|
0
|
0
|
-
|
|
| Cash from Financing |
26
|
36
|
27
|
41
|
-
|
|
| Stock Issued |
25
|
36
|
27
|
41
|
-
|
|
| Debt (LT) Issued |
1
|
0
|
0
|
0
|
-
|
|
| Free Cash Flow |
0
|
-44
|
-25
|
-14
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-20.4%
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
0.6
|
0.1
|
1.2
|
1.4
|
1.0
|
|
| Financial Leverage D/E |
-
|
-
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available